Drug Profile
Research programme: beta-adrenergic receptor gene therapy - University of Arkansas
Latest Information Update: 18 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 18 Apr 2002 No development reported - Preclinical for Asthma in USA (Injection)
- 07 Sep 2000 New profile
- 07 Sep 2000 The gene therapy product is available for licensing